

Introduction to Drug Utilization Research



Introduction to Drug Utilization Research 2003

Tittel: Introduction to Drug Utilization Research
Opplag: 2 500
Design: Grete Søimer
Foto: Photo Alto/Laurent Hamels
Trykk: Nordberg Aksidenstrykkeri AS

ISBN 82-8082-039-6
IN 0000-2069



2003

Introduction to Drug Utilization Research



World Health Organization

WHO International Working Group for Drug Statistics Methodology

WHO Collaborating Centre for Drug Statistics Methodology

**WHO Collaborating Centre for Drug Utilization Research and Clinical
Pharmacological Services**

WHO Library Cataloguing-in-Publication Data

Introduction to drug utilization research / WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services.

1. Drug utilization 2. Research 3. Manuals I.WHO International Working Group for Drug Statistics Methodology II.WHO Collaborating Centre for Drug Statistics Methodology III.WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services

ISBN 92 4 156234 X

(NLM classification: WB 330)

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Printed in Oslo, Norway, 2003

CONTENTS

Preface: Drug utilization research - the early work	6
Chapter 1: What is drug utilization research and why is it needed?	8
1.1 Definition and domains	8
1.2 Why drug utilization research?	9
1.2.1 Description of drug use patterns	9
1.2.2 Early signals of irrational use of drugs	10
1.2.3 Interventions to improve drug use - follow-up	10
1.2.4 Quality control of drug use	10
1.3 Drug utilization studies and drug policy decisions	11
1.4 General reading	12
Chapter 2: Types of drug use information	13
2.1 Drug-based information	13
2.1.1 Level of drug use aggregation	13
2.1.2 Indication	13
2.1.3 Prescribed daily doses	14
2.2 Problem or encounter-based information	15
2.3 Patient information	16
2.4 Prescriber information	16
2.5 Types of drug utilization study	17
2.6 Drug costs	17
2.7 General reading	18
2.8 Exercises	19
Chapter 3: Sources of data on drug utilization	20
3.1 Large databases	20
3.2 Data from drug regulatory agencies	20
3.3 Supplier (distribution) data	20
3.4 Practice setting data	21
3.4.1 Prescribing data	21
3.4.2 Dispensing data	22
3.4.3 Aggregate data	22
3.4.4 Over-the-counter and pharmacist-prescribed drugs	22
3.4.5 Telephone and Internet prescribing	22
3.5 Community setting data	23
3.6 Drug use evaluation	23
3.7 General reading	24
3.8 Exercises	24
Chapter 4: Economic aspects of drug use (pharmacoeconomy)	26
4.1 Introduction	26
4.2 Cost-minimization analysis	26
4.3 Cost-effectiveness analysis	26
4.4 Cost-utility analysis	27
4.5 Cost-benefit analysis	27
4.6 General reading	28
4.7 Exercises	28

Chapter 5: Drug classification systems	33
5.1 Different classification systems	33
5.2 The ATC classification system	33
5.3 Ambivalence towards an international classification system	35
5.4 Implementation of the ATC/DDD methodology	36
5.5 General reading	36
5.6 Exercises	37
Chapter 6: Drug utilization metrics and their applications	38
6.1 The concept of the defined daily dose (DDD)	38
6.2 Prescribed daily dose and consumed daily dose	39
6.3 Other units for presentation of volume	39
6.4 Cost	39
6.5 General reading	40
6.6 Exercises	41
Chapter 7: Solutions to the exercises	74
Acknowledgements	84

PREFACE:

DRUG UTILIZATION RESEARCH - THE EARLY WORK

The development of drug utilization research was sparked by initiatives taken in Northern Europe and the United Kingdom in the mid-1960s (1, 2). The pioneering work of Arthur Engel in Sweden and Pieter Siderius in Holland (3) alerted many investigators to the importance of comparing drug use between different countries and regions. Their demonstration of the remarkable differences in the sales of antibiotics in six European countries between 1966 and 1967 inspired WHO to organize its first meeting on «Drug consumption» in Oslo in 1969 (4). This led to the constitution of the WHO European Drug Utilization Research Group (DURG).

The pioneers of this research understood that a correct interpretation of data on drug utilization requires investigations at the patient level. It

became clear that we need to know the answers to the following questions:

- why drugs are prescribed;
- who the prescribers are;
- for whom the prescribers prescribe;
- whether patients take their medicines correctly;
- what the benefits and risks of the drugs are.

The ultimate goal of drug utilization research must be to assess whether drug therapy is rational or not. To reach this goal, methods for auditing drug therapy towards rationality are necessary.

The early work did not permit detailed comparisons of the drug utilization data obtained from different countries because the source and form of the information varied between them. To overcome this difficulty, researchers in Northern Ireland (United Kingdom), Norway and Sweden




Figure 1 Utilization of insulin and oral antidiabetic drugs in seven European countries from 1971-1980 expressed in defined daily doses (DDDs) per 1000 inhabitants per day. For comparison the prescribed daily doses (PDD) per 1000 inhabitants per day of oral antidiabetic drugs are given for Northern Ireland (UK) and Sweden for 1980 (indicated with an asterisk).

developed a new unit of measurement, initially called the agreed daily dose (5) and later the defined daily dose (DDD) (6). This unit was defined as **the average maintenance dose of the drug when used on its major indication in adults**. The first study used antidiabetic drugs as an example: it was found that the sum of the DDDs of insulin and oral antidiabetic drugs (about 20 DDDs per 1000 inhabitants per day) roughly corresponded to the morbidity due to diabetes after correction for the number of patients treated with dietary regimens alone. Among the first countries to adopt the DDD methodology was the former Czechoslovakia (7) and the first comprehensive national list of DDDs was published in Norway in 1975 (8). Another important methodological advance was the adoption of the uniform anatomical therapeutic chemical (ATC) classification of drugs (see chapter 5.2). The use of standardized methodology allowed meaningful comparisons of drug use in different countries to be made (Fig. 1).

Drug utilization research developed quickly during the following 30 years and soon became a respectable subject for consideration at international congresses in pharmacology, pharmacy and epidemiology. Particularly rapid developments were seen in Australia (9) and Latin America (10). The number of English-language papers on the subject listed in the *Cumulative index medicus* rose from 20 in 1973 (when the term «drug utilization» first appeared) to 87 in 1980, 167 in 1990, and 486 in 2000.

Scandinavica, 1984, Suppl. 683:7-9.

2. Dukes MNG. Development from Crooks to the nineties. In: *Auditing Drug Therapy. Approaches towards rationality at reasonable costs*. Stockholm, Swedish Pharmaceutical Press, 1992.
3. Engel A, Siderius P. *The consumption of drugs. Report on a study 1966-1967*. Copenhagen, WHO Regional Office for Europe, 1968 (EURO 3101).
4. *Consumption of drugs. Report on a symposium in Oslo 1969*. Copenhagen, WHO Regional Office for Europe, 1970 (EURO 3102).
5. Bergman U, et al. The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway, and Sweden. *European Journal of Clinical Pharmacology*, 1975;8:83-89.
6. Bergman U et al., eds. *Studies in drug utilization. Methods and applications*. Copenhagen, WHO Regional Office for Europe, 1979 (WHO Regional Publications, European Series No. 8).
7. Stika L et al. Organization of data collection in Czechoslovakia. In: Bergman U et al., eds. *Studies in drug utilization. Methods and applications*. WHO Regional Office for Europe, Copenhagen, 1979 (WHO Regional Publications European Series No. 8) pp.125-136.
8. Baksaas Aasen I et al. *Drug dose statistics, list of defined daily doses for drugs registered in Norway*. Oslo, Norsk Medicinal Depot, 1975.

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>